HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer

Conditions: Efficacy and Safety Interventions: Drug: HR070803; Drug: Oxaliplatin; Drug: Tegafur; Drug: Folinic acid; Drug: 5-Fluorouracil Sponsors: The First Affiliated Hospital with Nanjing Medical University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials